A Swiss biotech company working on engineering novel antibody therapeutics in allergy, inflammation and neurology, raises funding. 

Contentlockr

Zurich-based  Mabylon AG, a biotech company, has raised a total of CHF 30M (approximately €32M) in the form of both equity investment and convertible loan from existing private investors, with the major investment coming from former management and board members of Roche.

The funding will allow the Swiss company to advance its lead program MY006, a tri-specific antibody neutralising peanut allergens, to completion of a Phase Ia/b trial in 2027.

In addition, the capital will allow Mabylon to further develop its discovery and pre-clinical programs. These include MY010, a multi-specific and cross-reactive antibody targeting the birch Bet v 1 allergen, as well as all the major birch-related tree, fruit and nut allergens.

The funding will also support the development of MY011, an antibody product for treating grass pollen allergies. 

“We are very pleased to have closed a CHF 30 million financing agreement in such a challenging global funding environment. This is a strong validation of our approach using human-derived, multi-specific antibodies for the treatment of allergies,“ says Alcide Barberis, PhD, CEO of Mabylon. “We also warmly welcome Dr. Thomas Hecht to our Board of Directors. He brings outstanding industry expertise and will help us advance and commercialise our pipeline of best-in-class allergen-neutralising antibodies.”

At the shareholders’ assembly, Dr. Thomas Hecht was elected as a new member of Mabylon’s Board of Directors. He succeeds Prof. Adriano Aguzzi, whose term ended in June 2025.

Mabylon: Antibody therapeutics in allergy, inflammation and neurology

Led by Alcide Barberis, Mabylon focuses on using naturally occurring human antibodies to treat allergies, neurodegenerative diseases, and inflammation.

Human-derived antibodies are more effective than those from traditional sources like animal models or artificial libraries.

For example, Mabylon’s antibodies come from allergic patients and target important parts of allergens. This helps improve our understanding of allergies and how they progress.

The company’s goal is to rapidly create high-quality antibody libraries against validated targets from which the best functional, therapeutically relevant products are selected. To this aim, 

Mabylon has access to diverse sources of immune repertoires, focusing on patients with relevant conditions.

“MY006 is a multi-specific anti-allergen antibody for the prophylactic treatment of peanut allergy, an indication with a high unmet medical need. The funds will enable Mabylon to reach clinical proof-of-concept and further advance its early-stage pipeline,” said Gottlieb Keller, Chairman of Mabylon’s Board of Directors. “I would like to thank Prof. Adriano Aguzzi for his contributions to the board and welcome Thomas Hecht as a new board member.”